Current Medicinal Chemistry - Volume 10, Issue 1, 2003

Natural xanthonolignoids are formed by the coupling of cinnamyl alcohol with an appropriate ortho-dihydroxyxanthone. More than twenty xanthonolignoids have been isolated and synthesized and some interesting pharmacological activities of these compounds have been described.The purpose of this review is to describe the natural occurrence, isolation, structure elucidation and synthesis - both biomimetic and classic -as well as biological activities of xanthonolignoids. Aspects related to biosynthesis will also be considered.

The notion that medicines derived from plants depend for their action on active principles present has to be modified in view of the findings that there are, in many cases, adjuvant substances in the plant which enhance the activity of the components actually responsible for the effect. This synergy may involve protection of an active substance from degradation by enzymes, it may facilitate transport across barriers such as cell and organelle walls, it may overcome multi-drug resistance mechanisms or provide other signals to the host's cells that result in higher efficacy of the crude drug when compared with isolated components. The many plant substances that stimulate the immune system, often at very low doses, have not been reviewed as this is not strictly speaking synergy. Some of the evidence for the phenomena described is reviewed and its bearing on phytotherapy commented.

In this present review we report different synthetic methodologies for the preparation of fluoroquinolones and their biological properties. The appearance of the fluoroquinolones, a new class of antibacterial agents (based on nalidixic acid, 4-quinolone-3-carboxylates), in early 1980's, gave a new impulse for the international competition to synthesize more effective drugs. Fluoroquinolones have a broad spectrum of activity against Gram-positive, Gram-negative and mycobacterial organisms as well as anaerobes. The fluoroquinolone ciprofloxacin hydrochloride is an important bioterrorist weapon and also an antibiotic used to treat bacterial infection in many different parts of the body, approved for use in patients who have been exposed to the inhaled form of anthrax.

Irinotecan, a camptothecin analogue, is a prodrug which requires bioactivation to form the active metabolite SN-38. SN-38 acts as a DNA topoisomerase I poison. Irinotecan has been widely used in the treatment of metastatic colorectal cancer, small cell lung cancer and several other solid tumors. However, large inter-patient variability in irinotecan and SN-38 disposition, as well as severe but unpredictable diarrhea limits the clinical potential of irinotecan. Intense clinical pharmacology studies have been conducted to elucidate its complicated metabolic pathways and to provide scientific rationale in defining strategies to optimize drug therapy. Irinotecan is subjected to be shunted between CYP3A4 mediated oxidative metabolism to form two inactive metabolites APC or NPC and tissue carboxylesterase mediated hydrolysis to form SN-38 which is eventually detoxified via glucuronidation by UGT1A1 to form SN-38G. The pharmacology of this compound is further complicated by the existence of genetic inter-individual differences in activation and deactivation enzymes of irinotecan (e.g., CYP3A4, CYP3A5, UGT1A1) and sharing competitive elimination pathways with many concomitant medications, such as anticonvulsants, St. John's Wort, and ketoconazole. Efflux of the parent compound and metabolites out of cells by several drug transporters (e.g., Pgp, BCRP, MRP1, MRP2) also occurs. This review highlights the latest findings in drug activation, transport mechanisms, glucuronidation, and CYP3A-mediated drug-drug interactions of irinotecan in order to unlock some of its complicated pharmacology and to provide ideas for relevant future studies into optimization of this promising agent.

With the recent emergence of combinatorial chemistry and high-speed parallel synthesis for drug discovery applications, the multi-component reaction (MCR) has seen a resurgence of interest. Easily automated one-pot reactions, such as the Ugi and Passerini reactions, are powerful tools for producing diverse arrays of compounds, often in one step and high yield. Despite this synthetic potential, the Ugi reaction is limited by producing products that are flexible and peptide-like, often being classified as ‘non drug-like’. This review details developments of new, highly atom-economic MCR derived chemical methods, which enable the fast and efficient production of chemical libraries comprised of a variety of biologically relevant templates. Representative examples will also be given demonstrating the successful impact of MCR combinatorial methods at different stages of the lead discovery, lead optimization and pre-clinical process development arenas. This will include applications spanning biological tools, natural products and natural product-like diversity, traditional small molecule and ‘biotech’therapeutics respectively. In particular, this review will focus on applications of isocyanide based MCR (IMCR) reactions.